The Liquid Biopsy Consortium: Challenges and Opportunities for Early Cancer Detection and Monitoring

Overview

Journal Cell Rep Med

Publisher Cell Press

Specialties Biology
General Medicine

Date 2023 Sep 16

PMID 37716353

Authors

Syeda Maheen Batool

Anudeep Yekula

Prerna Khanna

Tiffaney Hsia

Austin S Gamblin

Emil Ekanayake

Ana K Escobedo

Dong Gil You

Cesar M Castro

Hyungsoon Im

Tugba Kilic

Michelle Andrea Garlin

Johan Skog

Daniela M Dinulescu

Jonathan Dudley

Nishant Agrawal

Jordan Cheng

Fereidoun Abtin

Denise R Aberle

David Chia

David Elashoff

Tristan Grognan

Kostyantyn Krysan

Scott S Oh

Charles Strom

Michael Tu

Fang Wei

Rena R Xian

Steven J Skates

David Y Zhang

Thi Trinh

Mark Watson

Rebecca Aft

Siddarth Rawal

Ashutosh Agarwal

Susan B Kesmodel

Changhuei Yang

Cheng Shen

Fred H Hochberg

David T W Wong

Abhijit A Patel

Nickolas Papadopoulos

Chetan Bettegowda

Richard J Cote

Sudhir Srivastava

Hakho Lee

Bob S Carter

Leonora Balaj

Affiliations

Soon will be listed here.

Abstract

The emerging field of liquid biopsy stands at the forefront of novel diagnostic strategies for cancer and other diseases. Liquid biopsy allows minimally invasive molecular characterization of cancers for diagnosis, patient stratification to therapy, and longitudinal monitoring. Liquid biopsy strategies include detection and monitoring of circulating tumor cells, cell-free DNA, and extracellular vesicles. In this review, we address the current understanding and the role of existing liquid-biopsy-based modalities in cancer diagnostics and monitoring. We specifically focus on the technical and clinical challenges associated with liquid biopsy and biomarker development being addressed by the Liquid Biopsy Consortium, established through the National Cancer Institute. The Liquid Biopsy Consortium has developed new methods/assays and validated existing methods/technologies to capture and characterize tumor-derived circulating cargo, as well as addressed existing challenges and provided recommendations for advancing biomarker assays.

Citing Articles

Multimodal Framework in Lung Cancer Management: Integrating Liquid Biopsy with Traditional Diagnostic Techniques.

Qi W, Tian L, Xu J, Li Z, Wang T Cancer Manag Res. 2025; 17:461-481.

PMID: 40060704 PMC: 11889406. DOI: 10.2147/CMAR.S506630.

Unraveling Tumor-to-Tumor Metastasis: Insights into Pathogenesis, Diagnostic Challenges, and Treatment Modalities.

Mei W, Zhang D Biologics. 2025; 19:43-58.

PMID: 40041727 PMC: 11878131. DOI: 10.2147/BTT.S505950.

Exploring the clinical utility of liquid biopsy with cfDNA in cancer: A systematic review.

Ranganathan K, Kurian N, Goswami H, Rishi K, Veldore V J Liq Biopsy. 2025; 5:100150.

PMID: 40027943 PMC: 11863880. DOI: 10.1016/j.jlb.2024.100150.

Next-Generation Sequencing Analysis on Image-Guided Biopsy Samples in Early-Stage Lung Cancer: Feasibility Study and Comparison With Surgical Samples.

Gros L, Yip R, Golombeck A, Yankelevitz D, Henschke C JTO Clin Res Rep. 2025; 6(2):100777.

PMID: 39877030 PMC: 11773006. DOI: 10.1016/j.jtocrr.2024.100777.

Liquid Biopsy and Multidisciplinary Treatment for Esophageal Cancer.

Hoshi Y, Matsuda S, Takeuchi M, Kawakubo H, Kitagawa Y Cancers (Basel). 2025; 17(2).

PMID: 39857978 PMC: 11763614. DOI: 10.3390/cancers17020196.

References

Konecny M, Markus J, Waczulikova I, Dolesova L, Kozlova R, Repiska V . The value of SHOX2 methylation test in peripheral blood samples used for the differential diagnosis of lung cancer and other lung disorders. Neoplasma. 2016; 63(2):246-53. DOI: 10.4149/210_150419N208. View

Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano A, Hoon D . Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem. 2010; 57(1):84-91. DOI: 10.1373/clinchem.2010.151845. View

Tsai W, Chen J, Shao H, Wu J, Lai J, Lu S . Circulating Tumor Cell Count Correlates with Colorectal Neoplasm Progression and Is a Prognostic Marker for Distant Metastasis in Non-Metastatic Patients. Sci Rep. 2016; 6:24517. PMC: 4830949. DOI: 10.1038/srep24517. View

Wei F, Strom C, Cheng J, Lin C, Hsu C, Soo Hoo G . Electric Field-Induced Release and Measurement Liquid Biopsy for Noninvasive Early Lung Cancer Assessment. J Mol Diagn. 2018; 20(6):738-742. PMC: 6198245. DOI: 10.1016/j.jmoldx.2018.06.008. View

Matamala N, Vargas M, Gonzalez-Campora R, Minambres R, Arias J, Menendez P . Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem. 2015; 61(8):1098-106. DOI: 10.1373/clinchem.2015.238691. View

Chen K, Lou F, Yang F, Zhang J, Ye H, Chen W . Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing. Sci Rep. 2016; 6:31985. PMC: 4995492. DOI: 10.1038/srep31985. View

Li W, Wang Y, Zhang Q, Tang L, Liu X, Dai Y . MicroRNA-486 as a Biomarker for Early Diagnosis and Recurrence of Non-Small Cell Lung Cancer. PLoS One. 2015; 10(8):e0134220. PMC: 4523212. DOI: 10.1371/journal.pone.0134220. View

Grasselli J, Elez E, Caratu G, Matito J, Santos C, Macarulla T . Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol. 2017; 28(6):1294-1301. PMC: 5834108. DOI: 10.1093/annonc/mdx112. View

Nelson N . Circulating tumor cells: will they be clinically useful?. J Natl Cancer Inst. 2010; 102(3):146-8. DOI: 10.1093/jnci/djq016. View

10.

Lee B, Mahmud I, Marchica J, Derezinski P, Qi F, Wang F . Integrated RNA and metabolite profiling of urine liquid biopsies for prostate cancer biomarker discovery. Sci Rep. 2020; 10(1):3716. PMC: 7048821. DOI: 10.1038/s41598-020-60616-z. View

11.

Tanaka F, Yoneda K, Kondo N, Hashimoto M, Takuwa T, Matsumoto S . Circulating tumor cell as a diagnostic marker in primary lung cancer. Clin Cancer Res. 2009; 15(22):6980-6. DOI: 10.1158/1078-0432.CCR-09-1095. View

12.

Bronkhorst A, Wentzel J, Aucamp J, van Dyk E, du Plessis L, Pretorius P . Characterization of the cell-free DNA released by cultured cancer cells. Biochim Biophys Acta. 2015; 1863(1):157-65. DOI: 10.1016/j.bbamcr.2015.10.022. View

13.

Kern S . Why your new cancer biomarker may never work: recurrent patterns and remarkable diversity in biomarker failures. Cancer Res. 2012; 72(23):6097-101. PMC: 3513583. DOI: 10.1158/0008-5472.CAN-12-3232. View

14.

Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T . Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro Oncol. 2010; 12(2):173-80. PMC: 2940579. DOI: 10.1093/neuonc/nop041. View

15.

Yang Z, LaRiviere M, Ko J, Till J, Christensen T, Yee S . A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2020; 26(13):3248-3258. PMC: 7334066. DOI: 10.1158/1078-0432.CCR-19-3313. View

16.

Lee Y, Tan Y, Oon C . Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol. 2018; 834:188-196. DOI: 10.1016/j.ejphar.2018.07.034. View

17.

Hamam R, Ali A, Alsaleh K, Kassem M, Alfayez M, Aldahmash A . microRNA expression profiling on individual breast cancer patients identifies novel panel of circulating microRNA for early detection. Sci Rep. 2016; 6:25997. PMC: 4867432. DOI: 10.1038/srep25997. View

18.

Zhu X, Weiser E, Jacobson D, Griffin J, Limburg P, Finney Rutten L . Provider-perceived barriers to patient adherence to colorectal cancer screening. Prev Med Rep. 2022; 25:101681. PMC: 8800035. DOI: 10.1016/j.pmedr.2021.101681. View

19.

Mathai R, Vidya R, Reddy B, Thomas L, Udupa K, Kolesar J . Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. J Clin Med. 2019; 8(3). PMC: 6463095. DOI: 10.3390/jcm8030373. View

20.

Sun J, Fei F, Zhang M, Li Y, Zhang X, Zhu S . The role of SEPT9 in screening, diagnosis, and recurrence monitoring of colorectal cancer. BMC Cancer. 2019; 19(1):450. PMC: 6518628. DOI: 10.1186/s12885-019-5663-8. View